QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 2, 2022.

QuidelOrtho Reports Third Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (NASDAQ: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the third quarter ended October 2, 2022.

QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022

SAN DIEGO--(BUSINESS WIRE)-- #LymeDisease--Lyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection. One answer is found in the discovery of novel drugs; and the breakthrough efforts taking place in this arena are the subject of a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for success

Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

Based on our previous four coverages of QuidelOrtho, we compiled our views and determined whether its fundamentals had changed or remained, based on its latest earnings results. Compared to competitors, we believe Quidel is less competitive than its larger peers such as Roche and Abbott, but believe its smaller size presents a longer runway for growth.

QuidelOrtho: Fundamentals Remain, Upbeat Financials

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York beginning on September 12, 2022, with a fireside chat scheduled for 4:50 p.m. ET / 1:50 p.m. PT. Interested parties

QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)-- #LymeDisease--The National Institutes of Health reports that bacterial biofilms are responsible for up to 75% of all infectious diseases in humans, including infections of wounds, the lungs and the urinary tract. This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. The webinar, available at https://edu

Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its board of directors has authorized the repurchase of up to $300 million of shares of QuidelOrtho's common stock over the next two years. “This announcement just months after the close of QuidelOrtho's formative transaction reflects the substantial

QuidelOrtho Announces $300 Million Share Repurchase Authorization

The earnings of the former Quidel, a diagnostic testing company, exploded in 2020 because of COVID-19, and have been going strong ever since. The market doesn't believe this "nouveau riche" story, valuing the company at a single-digit multiple of current earnings.

The Market Doesn't Believe QuidelOrtho's Good Fortune

QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.

QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View

QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.55% and 7.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

QuidelOrtho (QDEL) Q2 Earnings Miss Estimates

QuidelOrtho Corporation (NASDAQ:QDEL ) Q2 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Bryan Brokmeier - Vice President, Investor Relations Douglas Bryant - Chairman and CEO Joseph Busky - CFO Conference Call Participants Jack Meehan - Nephron Research Andrew Cooper - Raymond James Casey Woodring - JP Morgan Alex Nowak - Craig Hallum Operator Welcome to the QuidelOrtho's Second Quarter 2022 Financial Results Conference Call and Webcast. At this time, all participants lines are in a listen-only mode.

QuidelOrtho Corporation (QDEL) CEO Douglas Bryant on Q2 2022 - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a leading in vitro diagnostics company, today announced financial results for the second quarter ended July 3, 2022. The Company reported total revenue for the second quarter of 2022 of $613.4 million, a 247% increase as reported, compared to $176.6 million for the second quarter of 2021. This was largely due to the consummation of the business combination that occurred on May 27, 2022 pursuant

QuidelOrtho Reports Second Quarter 2022 Financial Results

QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.

What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings?

Company receives top customer rating in the 2022 IMV ServiceTrak™ Awards SAN DIEGO , July 26, 2022 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ: QDEL) ("QuidelOrtho") announced today that its subsidiary, Ortho Clinical Diagnostics, a leading provider of in vitro diagnostics solutions and services to hospitals, clinical laboratories and blood banks around the world, has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2022 IMV ServiceTrak™ Awards for the fifth consecutive year.

ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a leading in vitro diagnostics company, today announced it will report financial results for its second quarter 2022 ended July 3, 2022, after the market close on Thursday, August 4, 2022.

QuidelOrtho to Report Second Quarter 2022 Financial Results on August 4, 2022

QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can QuidelOrtho (QDEL) Keep the Earnings Surprise Streak Alive?

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

3 Reasons to Add QuidelOrtho (QDEL) Stock to Your Portfolio Now

Boyd Gaming

Jones Lang LaSalle

Lithia Motors

Everest RE Group

Steady sales growth is the key to survival for a business, even during recessions. Let's check at Boyd Gaming (BYD), Lithia Motors (LAD), Everest Re (RE), Jones Lang LaSalle (JLL) & QuidelOrtho (QDEL) that are recording top-line growth.

5 Stocks With Robust Sales Growth to Beat Recession Woes

Investors need to pay close attention to QuidelOrtho (QDEL) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in QuidelOrtho (QDEL) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is QuidelOrtho (QDEL) a Great Value Stock Right Now?

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) — QuidelOrtho announces that its subsidiary, Quidel Corporation, is collaborating with the American Heart Association, the leading voluntary health organization devoted to a world of longer and healthier lives, to improve the health of San Diego residents and deconstruct barriers to equitable health in our communities. Quidel Corporation will invest funding totaling $750,000 and support over the next three years

Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County

QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

QuidelOrtho (QDEL) Stock Jumps 3.9%: Will It Continue to Soar?

SAN DIEGO--(BUSINESS WIRE)-- #LymeDisease--With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel's recently formed Lyme Task Force Team—the only one of its kind—today announced a multitiered collaboration with Global Lyme Alliance to dramatically heighten public awareness to a health condition afflicting nearly half a million Americans each year. Quidel is the nation's leading developer of the only rap

Quidel Corp.—Developer of Only FDA-Cleared FIA Rapid Point-of-Care Diagnostic Lyme Disease Test—To Partner With Renowned Global Lyme Alliance to Dramatically Heighten Lyme Disease Awareness

Quidel (QDEL) reported earnings 30 days ago. What's next for the stock?

News for QuidelOrtho Corp Stock (QDEL)